Navigation Links
GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
Date:6/20/2008

Data being made available on NCI Database Could Save Drug Development Time

and Capital for Other Research Institutions

PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- Marking another positive step in the collaborative fight against cancer, GlaxoSmithKline (NYSE: GSK) announced today the release of genomic profiling data for over 300 cancer cell lines via the National Cancer Institute's cancer Bioinformatics Grid(TM) (caBIG(TM)). The caBIG(TM) initiative is a network of infrastructure and tools that enables the collection, analysis, and sharing of data and knowledge along the entire research pathway from laboratory bench to patient bedside. By releasing the cell line data via caBIG(TM), GSK could be enabling other cancer research institutions to save considerable drug development time and capital in their future cancer therapeutic research.

"These data are valuable for many avenues of cancer research, and we are pleased to share them with the cancer community," said Paolo Poletti, M.D., Senior Vice President, Oncology Medicines Development Center, R&D, GlaxoSmithKline. "Vast amounts of data are being generated in biomedical research and in order to realize the potential benefits of molecular medicine, scientists need to be able to access data in more timely and cost-efficient ways. The caBIG(TM) platform is an excellent tool to do just that."

With the advent of the human genome project, researchers have been able to identify, aggregate and analyze cancer cell line information in the laboratory. These breakthrough bodies of data have been used extensively in the discovery and development of novel cancer therapeutics.

According to Dr. Richard Wooster, Director of Translational Medicine Oncology, R&D, GSK, "Cataloging this type of information in a network like caBIG(TM) leads to a ready-made body of biologic information that can be mined by all cancer researchers to further everyone's understanding of cancer. In turn, we hope this data will further drive the identification of predictive biomarkers and lead to shorter, more directed clinical trials allowing us to bring drugs more quickly to patients who need them."

The genomic data being shared by GSK through caBIG(TM) come from cell lines derived from a wide variety of tumors, including breast, prostate, lung and ovarian cancers. Researchers at academic institutions, small research facilities and non-profit organizations may benefit by not having to incur the prohibitive cost and time involved in identifying and cataloging each cell line.

"The ability for researchers to share data via the caBIG(TM) network is exactly what this initiative was designed to enable," said Robert Clarke, Ph.D., D.Sc., professor of oncology and physiology and biophysics at the Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital. "As more scientists throughout the cancer community, in the US and globally, use caBIG(TM) and find it easy to share data and collaborate, both basic and clinical research will be improved. We're excited about what this cancer cell data might provide to other researchers and we also hope it will be a catalyst for other organizations to follow the GSK example."

The NCI launched the caBIG(TM) initiative in 2004 to accelerate the research and discovery of new approaches to the detection, diagnosis, treatment, and prevention of cancer. Since that time, more than 200 organizations and 1000 individuals have helped to create more than 40 biomedical research tools such as caArray, the microarray data management system that is guiding the annotation and supporting the exchange of the cancer cell array data provided by GSK.

Interested researchers can download this free data through caArray at https://cabig.nci.nih.gov/tools/caArray_GSKdata. caArray, like all the tools in the caBIG(TM) suite, is free and open-source.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

About caBIG(TM)

The National Cancer Institute's cancer biomedical Informatics Grid(TM) (caBIG(TM)) is an information network that enables data and knowledge to be shared within and across organizations, scientific domains, and countries to accelerate the discovery of new approaches for the detection, diagnosis, treatment, and prevention of cancer. Cancer centers, research facilities, and other organizations from across the country are already getting connected with caBIG(TM), and caBIG(TM)-compatible tools and infrastructure are being adopted throughout the cancer and biomedical community. https://cabig.nci.nih.gov/


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that ... Dough Bar, has ignited an undeniable buzz in the protein product community by ... just any doughnut.  These doughnuts are packed with 11 grams of protein and made ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... provide strategic sales leadership and to further develop their rapidly expanding portfolio of ... Business Administration with a concentration in Marketing and an M.B.A. with concentration in ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... efforts for several years, and the efforts have paid off. Since implementation ... new standards of care to enhance perioperative patient experiences and reduce costly complications. ...
(Date:5/26/2016)... ... , ... Dr. LeRoy Perry’s recently authored whitepaper, “Tech Neck and ROI (return ... of users, hundreds of millions of whom are coming into the workplace with pain ... common action of looking down at hand-held technology devices (tablets, smartphones) for extended periods ...
Breaking Medicine News(10 mins):